SCHEMBL8265247

SCHEMBL8265247

COCCN(CCOC)Cc1ccc(B(O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LPL P06858 7/20 0.46
LIPG Q9Y5X9 7/20 0.46
CA2 P00918 3/20 0.41
CA1 P00915 2/20 0.41
ENPP2 Q13822 2/20 0.41
F11 P03951 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
MGLL Q99685 1/20 0.39
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20548501 0.92 LPL (0.46) MEN1KMT2ALPLLIPGCA2
SCHEMBL29956793 0.81 ENPP2 (0.52) MEN1KMT2ALPLLIPGENPP2
SCHEMBL3746659 0.80 MEN1 (0.50) MEN1KMT2AHRH3SMN1; SMN2MAPT
SCHEMBL29954989 0.79 LPL (0.42) MEN1KMT2ALPLLIPGCA2
SCHEMBL15450887 0.78 LPL (0.47) MEN1KMT2ALPLLIPGCA2
SCHEMBL29955372 0.77 MAPT (0.61) LPLLIPGCA2CA1F11
SCHEMBL3143360 0.77 MAPT (0.59) MEN1KMT2ACA2HRH3MAPT
SCHEMBL28451270 0.76 LPL (0.59) LPLLIPGCA2CA1F11
SCHEMBL8281042 0.76 MEN1 (0.51) MEN1KMT2ASMN1; SMN2
SCHEMBL14231018 0.76 LPL (0.61) LPLLIPGCA2CA1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 US disclosed
EP-2177518-A1 Organic compounds Novartis AG (CH) 2010-04-21 EP disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 US disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263560-A1 Organic Compounds REN, ACE, OTC MEN1 2812/4885KMT2A 2850/4885LPL 1162/4885
US-20090312304-A1 ORGANIC COMPOUNDS REN, ACE, PIGO MEN1 2792/4885KMT2A 3979/4885LPL 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.